^
    No biomarker
    Ewing Sarcoma
    dactinomycin
    Sensitive: A1 - Approval
    No biomarker
    Ewing Sarcoma
    IE
    Sensitive: A2 - Guideline
    No biomarker
    Ewing Sarcoma
    VC
    Sensitive: A2 - Guideline
    No biomarker
    Ewing Sarcoma
    GT
    Sensitive: A2 - Guideline
    No biomarker
    Ewing Sarcoma
    melphalan + busulfan
    Sensitive: A2 - Guideline
    No biomarker
    Ewing Sarcoma
    ifosfamide + cyclophosphamide oral + etoposide IV + topotecan
    Sensitive: A2 - Guideline
    No biomarker
    Ewing Sarcoma
    temozolomide + irinotecan
    Sensitive: A2 - Guideline
    No biomarker
    Ewing Sarcoma
    temozolomide + irinotecan + vincristine
    Sensitive: A2 - Guideline
    No biomarker
    Ewing Sarcoma
    cyclophosphamide oral + topotecan
    Sensitive: A2 - Guideline
    No biomarker
    Ewing Sarcoma
    carboplatin + ifosfamide + etoposide IV
    Sensitive: A2 - Guideline
    No biomarker
    Ewing Sarcoma
    gemcitabine + docetaxel
    Sensitive: A2 - Guideline
    No biomarker
    Ewing Sarcoma
    cabozantinib tablet
    Sensitive: A2 - Guideline
    TMB-H
    Ewing Sarcoma
    pembrolizumab
    Sensitive: A2 - Guideline
    MSI-H/dMMR
    Ewing Sarcoma
    pembrolizumab
    Sensitive: A2 - Guideline
    No biomarker
    Ewing Sarcoma
    VIDE
    Sensitive: A2 - Guideline
    No biomarker
    Ewing Sarcoma
    VAI
    Sensitive: A2 - Guideline
    No biomarker
    Ewing Sarcoma
    VDC
    Sensitive: A2 - Guideline
    No biomarker
    Ewing Sarcoma
    SP2577
    Sensitive: B - Late Trials
    No biomarker
    Ewing Sarcoma
    TK216
    Sensitive: B - Late Trials
    MGMT promoter methylation
    Ewing Sarcoma
    temozolomide + irinotecan
    Sensitive: C2 – Inclusion Criteria
    IGF1R underexpression
    Ewing Sarcoma
    mTOR inhibitor + IGF-1R inhibitor
    Sensitive: C3 – Early Trials
    IGF1 elevation
    Ewing Sarcoma
    CP-751,871
    Sensitive: C3 – Early Trials
    PTPRD R995C
    Ewing Sarcoma
    mTOR inhibitor + IGF-1R inhibitor
    Sensitive: C3 – Early Trials
    PTPRD V253I + PTPRD W775stop
    Ewing Sarcoma
    mTOR inhibitor + IGF-1R inhibitor
    Sensitive: C3 – Early Trials
    PTPRD V253I + PTPRD W775stop
    Ewing Sarcoma
    IGF-1R inhibitor
    Sensitive: C3 – Early Trials
    SPARC overexpression
    Ewing Sarcoma
    albumin-bound paclitaxel
    Sensitive: C3 – Early Trials
    EWSR1-FLI1 fusion
    Ewing Sarcoma
    VDC
    Sensitive: C4 – Case Studies
    FGFR3 amplification + FGFR4 amplification + FLT4 amplification
    Ewing Sarcoma
    trametinib + pazopanib
    Resistant: C4 – Case Studies
    IGF1R expression
    Ewing Sarcoma
    IGF-1R inhibitor
    Sensitive: D – Preclinical
    EWSR1-FLI1 fusion
    Ewing Sarcoma
    CDK12 inhibitor
    Sensitive: D – Preclinical
    FUS-ERG fusion
    Ewing Sarcoma
    ASP7487
    Sensitive: D – Preclinical
    CDKN2A deletion
    Ewing Sarcoma
    ASP7487
    Sensitive: D – Preclinical
    PAK4 deletion
    Ewing Sarcoma
    ASP7487
    Sensitive: D – Preclinical
    FUS-ERG fusion
    Ewing Sarcoma
    palbociclib
    Sensitive: D – Preclinical
    PAK4 deletion
    Ewing Sarcoma
    palbociclib
    Sensitive: D – Preclinical
    CDKN2A deletion
    Ewing Sarcoma
    palbociclib
    Sensitive: D – Preclinical
    CASP8 overexpression
    Ewing Sarcoma
    AMG 655
    Sensitive: D – Preclinical
    KDM1A overexpression
    Ewing Sarcoma
    SP2577
    Sensitive: D – Preclinical